Top Back to top

Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Chronic Malignancies Working Party (CMWP)
Study number:
42205674
Short title:
 
Study status:
Analysis
Deadline for data collection:
 
Study design:
Retrospective study design
Primary objective:
To evaluate the impact of additional adverse cytogenetic abnormalities on relapse-free survival after allo-SCT in MDS with very poor risk cytogenetics.
Key inclusion criteria:
 MDS
 CR1, CR2 and beyond
 Age >= 18
 MDS with more than 3 cytogenetic abnormalities at diagnosis
 First allogeneic SCT
 Allogeneic SCT from matched family or matched unrelated donor between 2000 and 2016
Country:
 
Principal investigator:
Xavier Poiré
Principal investigator email:
 
EBMT Study coordinator:
Linda Koster
Study coordinator email:
cmwpebmt@lumc.nl